SI2219451T1 - Postopek za zdravljenje hematopoetskih neoplazem - Google Patents

Postopek za zdravljenje hematopoetskih neoplazem

Info

Publication number
SI2219451T1
SI2219451T1 SI200831365T SI200831365T SI2219451T1 SI 2219451 T1 SI2219451 T1 SI 2219451T1 SI 200831365 T SI200831365 T SI 200831365T SI 200831365 T SI200831365 T SI 200831365T SI 2219451 T1 SI2219451 T1 SI 2219451T1
Authority
SI
Slovenia
Prior art keywords
hematopoietic neoplasms
treating hematopoietic
treating
neoplasms
hematopoietic
Prior art date
Application number
SI200831365T
Other languages
English (en)
Inventor
David Chaplin
Bronwyn G. Siim
Original Assignee
Oxigene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene, Inc. filed Critical Oxigene, Inc.
Publication of SI2219451T1 publication Critical patent/SI2219451T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
SI200831365T 2007-11-21 2008-11-21 Postopek za zdravljenje hematopoetskih neoplazem SI2219451T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98978607P 2007-11-21 2007-11-21
EP08851754.5A EP2219451B1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms
PCT/US2008/084427 WO2009067706A1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms

Publications (1)

Publication Number Publication Date
SI2219451T1 true SI2219451T1 (sl) 2015-02-27

Family

ID=40667883

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831365T SI2219451T1 (sl) 2007-11-21 2008-11-21 Postopek za zdravljenje hematopoetskih neoplazem

Country Status (12)

Country Link
US (4) US20090264382A1 (sl)
EP (1) EP2219451B1 (sl)
JP (1) JP5302328B2 (sl)
AU (1) AU2008326251B2 (sl)
CA (1) CA2703283C (sl)
DK (1) DK2219451T3 (sl)
ES (1) ES2529434T3 (sl)
HR (1) HRP20150040T1 (sl)
PL (1) PL2219451T3 (sl)
PT (1) PT2219451E (sl)
SI (1) SI2219451T1 (sl)
WO (1) WO2009067706A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075016A1 (en) * 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
CA2703283C (en) 2007-11-21 2016-01-12 Oxigene, Inc. Method for treating hematopoietic neoplasms
WO2012088438A1 (en) * 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
EP3700632A4 (en) * 2017-10-25 2021-08-25 Bionomics Limited METHOD OF TREATMENT OF ACUTE MYELOID LEUKEMIA
MX2021008523A (es) * 2019-01-15 2021-11-12 Ptc Therapeutics Inc Metodo para tratar una leucemia mieloide aguda.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
JP2001518935A (ja) 1997-03-26 2001-10-16 バイオソース テクノロジーズ，インコーポレイティド 抗癌剤としてのジ―アリールエーテル類及びそれらの誘導体
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JP2002500184A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ フェンスタチンとそのプロドラッグの合成
ATE476436T1 (de) 1998-01-09 2010-08-15 Univ Arizona Synthese von combretastatin a-4 prodrugs
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
US6433012B1 (en) 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
CA2324347A1 (en) 1998-03-25 1999-09-30 Nahid Waleh Benzoates derivatives for inhibiting angiogenesis
ATE328599T1 (de) 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
AU2190700A (en) 1998-12-17 2000-07-03 Tularik Inc. Tubulin-binding agents
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
CA2358925C (en) 1999-02-18 2010-04-20 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
CO5170498A1 (es) 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US6201001B1 (en) 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
JP2004505888A (ja) * 2000-03-10 2004-02-26 ベイラー・ユニバーシテイ チューブリン結合リガンドおよび対応するプロドラッグ構造
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
ATE527271T1 (de) 2000-04-27 2011-10-15 Univ Arizona Prodrugs von combretastatin a-1 phosphat und combretastatin b-1 phosphat
WO2001081288A1 (en) 2000-04-27 2001-11-01 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Hydroxyphenstatin and the prodrugs thereof
EP1283672B1 (en) 2000-05-09 2004-11-17 Arizona Board of Regents, acting for and on behalf of Arizona State University Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
AU2001261474B2 (en) * 2000-05-15 2006-03-09 Celgene Corporation Compositions and methods for the treatment of cancer
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US6743937B2 (en) * 2000-07-17 2004-06-01 Oxigene, Inc. Efficient method of synthesizing combretastatin A-4 prodrugs
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US7220784B2 (en) 2000-12-21 2007-05-22 John Anthony Hadfield Substituted stilbenes and their reactions
EP1351573A4 (en) * 2000-12-22 2007-03-28 Bristol Myers Squibb Co METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
GB2377469B (en) 2001-07-13 2005-07-06 Prismo Ltd Method and apparatus for laying a traffic calming surface
JP2005507912A (ja) 2001-10-26 2005-03-24 オキシジーン， インコーポレイテッド 改良型血管標的化剤としての官能化スチルベン誘導体
GB0126889D0 (en) 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
EP1465852A4 (en) 2001-12-21 2006-04-26 Univ Arizona SYNTHESIS OF COMBRETASTATIN? A? 2? PRODRUGS
EP1515716A2 (en) 2002-04-03 2005-03-23 Astrazeneca AB Indole derivatives having anti-angiogenetic activity
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040024696A1 (en) 2002-08-02 2004-02-05 Federico Alves System for automatically transferring funds
TW549690U (en) 2002-11-13 2003-08-21 Tekcon Electronics Corp Electrical card connector
EP1601348A4 (en) 2003-02-28 2008-12-10 Oxigene Inc Compositions and methods with improved therapeutic activity
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
CA2611712C (en) 2005-06-14 2014-05-13 Baylor University Combretastatin analogs with tubulin binding activity
CA2703283C (en) 2007-11-21 2016-01-12 Oxigene, Inc. Method for treating hematopoietic neoplasms

Also Published As

Publication number Publication date
CA2703283A1 (en) 2009-05-28
HRP20150040T1 (hr) 2015-02-27
AU2008326251B2 (en) 2014-03-06
US20120270831A1 (en) 2012-10-25
US20090264382A1 (en) 2009-10-22
DK2219451T3 (en) 2015-01-12
CA2703283C (en) 2016-01-12
EP2219451A1 (en) 2010-08-25
JP5302328B2 (ja) 2013-10-02
EP2219451B1 (en) 2014-11-12
US20090192098A1 (en) 2009-07-30
JP2011504510A (ja) 2011-02-10
AU2008326251A1 (en) 2009-05-28
US9040500B2 (en) 2015-05-26
US20150246064A1 (en) 2015-09-03
WO2009067706A1 (en) 2009-05-28
PL2219451T3 (pl) 2015-04-30
PT2219451E (pt) 2015-02-09
ES2529434T3 (es) 2015-02-20
EP2219451A4 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL209895A0 (en) Compounds for treating beta-amyloidoses
ZA201001753B (en) Method for consumer-dispenser interactions
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
PL2376410T3 (pl) Sposób suszenia
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
IL209894A0 (en) Compounds for treating amyloidoses
GB0803107D0 (en) Method
EP2174912A4 (en) PROCESS FOR MACHINING A COPPER ARSEN COMPOUND
HK1203516A1 (en) Methods for treating psoriasis
PL2301893T3 (pl) Sposób oczyszczania ścieku
IL213476A0 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
IL210097A0 (en) Compositions and methods for treating unfluenza
HUE044194T2 (hu) Besugárzó berendezés
GB0806792D0 (en) Co-Existence method
IL213398A0 (en) Compounds for treating cancer
HK1203305A1 (en) Methods for treating psoriasis
EP2214776C0 (en) IMPOTENCE TREATMENT DEVICE
IL212212A0 (en) Compound useful for treating cellulite
PL2376597T3 (pl) Proces obróbki odpadów
HK1156900A1 (en) Powder treating apparatus
PL2219451T3 (pl) Sposób leczenia nowotworów tkanek krwiotwórczych
EP2144888A4 (en) METHODS OF TREATING CANCER
EP2231150A4 (en) METHOD FOR SEARCH TREATMENT WITH CROSS-COMPOSITE COMPOSITIONS
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS